Neuraxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuraxis, Inc. (NRXS) on July 5, 2024, covering events occurring on June 28, 2024. The Company, incorporated in Delaware and listed on NYSE American, is an emerging growth company. The filing primarily addresses the departure of directors or principal officers and compensatory arrangements under Item 5.02.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to director compensation:
- Stock Price: $2.78 per share (closing price on June 28, 2024).
- Director Compensation: Quarterly equity awards valued at $12,500 per non-employee director, totaling $50,000 annually per director.
- Grant Details: Shares were issued as unrestricted stock awards, fully vested immediately, to three non-employee directors (Kristin Ferge, Beth Keyser, and Bradley Mitch Watkins).
Material Changes
The filing reports the first issuance of securities under the Company's 2022 Omnibus Securities and Incentive Plan following its August 2023 initial public offering. The shares were issued to settle accrued compensation for services provided through March 31, 2024. No material changes to revenue, operations, or capital structure are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of specific risks and contingencies beyond the standard disclosure of the stock award agreements. The Company indicated it plans to utilize the attached Unrestricted Stock Award Agreement form for future unrestricted stock awards under the Plan.
Investor Verification Checklist
- Verify the total number of shares issued to each director based on the $12,500 value and $2.78 share price.
- Review the full text of the Unrestricted Stock Award Agreement (Exhibit 10.1) for specific terms and conditions.
- Confirm the impact of these equity grants on the Company's total authorized share count and potential dilution.
- Check subsequent filings for the Company's quarterly financial results, as this 8-K does not contain revenue or earnings data.